• IMA sites
  • IMAJ services
  • IMA journals
  • Follow us
  • Alternate Text Alternate Text
עמוד בית
Sun, 24.11.24

Search results


May 2002
Kobi Peleg, PhD, Haim Reuveni, MD and Michael Stein, MD
Eyal Grunebaum, MD and Chaim M. Roifman, MD

Hemophagocytic lymphohistiocytosis is thought to occur as a primary (familial) form or secondary to infection or malignancy. Recently, several defects in genes important for immune functions were identified in patients with HLH[1]. These include mutations in perforin, the gamma common chain, the receptor for interleukin-2, Slap and purine nucleoside phosphorylase. Since abnormal function of these genes is associated with a wide clinical spectrum, HLH is probably another manifestation of immune deficiency and a thorough immune evaluation should be done in all such patients.






[1] HLH = hemophagocytic lymphohistiocytosis


Ori Efrati, MD, Asher Barak, MD, Jacob Yahav, MD, Lea Leibowitz, MD, Nathan Keller, MD and Yoram Bujanover, MD
David Hazzan, MD, Gil Peer, MD and Eitan Shiloni, MD
Aneta Lazarov, MD, Keren Moss, MD, Natalie Plosk, MD, Mario Cordoba, MD and Liliana Baitelman, Pharm
Gahl Greenberg, MD, Myra Shapiro-Feinberg, MD and Rivka Zissin, MD
Legal Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal or medical advice on any matter.
The IMA is not responsible for and expressly disclaims liability for damages of any kind arising from the use of or reliance on information contained within the site.
© All rights to information on this site are reserved and are the property of the Israeli Medical Association. Privacy policy

2 Twin Towers, 35 Jabotinsky, POB 4292, Ramat Gan 5251108 Israel